Cargando…
Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC
INTRODUCTION: Programmed cell death 1 (PD-1) inhibitors have become standard treatment for patients with advanced NSCLC. However, few studies have focused on the impact of cancer cachexia on the efficacy of PD-1 or programmed death-ligand 1 (PD-L1) inhibitors among patients with NSCLC. METHODS: We r...
Autores principales: | Miyawaki, Taichi, Naito, Tateaki, Kodama, Akihro, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kawamura, Takahisa, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Notsu, Akifumi, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, Takahashi, Toshiaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474252/ https://www.ncbi.nlm.nih.gov/pubmed/34589927 http://dx.doi.org/10.1016/j.jtocrr.2020.100020 |
Ejemplares similares
-
Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer
por: Nishioka, Naoya, et al.
Publicado: (2020) -
Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
por: Kodama, Hiroaki, et al.
Publicado: (2021) -
Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy
por: Miyawaki, Taichi, et al.
Publicado: (2020) -
Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer
por: Miyawaki, Taichi, et al.
Publicado: (2022) -
Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study
por: Miyawaki, Taichi, et al.
Publicado: (2021)